C Declaye1, A L Sennesael2,3, A S Larock1,3, A Spinewine1,2,3, B Krug4,5. 1. Department of Pharmacy, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium. 2. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 3. Namur Thrombosis and Hemostasis Center (NTHC), Universite de Namur, Namur, Belgium. 4. Quality and Safety Officer, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium. 5. Institute of Health and Society, Université catholique de Louvain, Brussels, Belgium.
Abstract
BACKGROUND: Potential inappropriate use of direct oral anticoagulants (DOACs) increases the risk of thromboembolic and haemorrhagic events. PURPOSE: To determine the net cost benefit of clinical pharmacy interventions on the prescription of DOACs. METHOD: We constructed a decision tree model using a public payer perspective. The appropriateness of the prescription was assessed using the Medication Appropriateness Index. The theoretical risks were collected from the literature and the individual potential risks were calculated using the Nesbit risk assignment conducted by two independent clinical pharmacists. Different costs were included based on diagnosis-related group coding and data in the literature. A univariate sensitivity analysis was performed. RESULTS: Thirty-six of 75 patients had an inappropriate prescription of DOACs. The saved difference between avoided costs (7954€) and annualised medication costs and pharmacist cost (4323€) was 3631€ for 75 patients. CONCLUSIONS: In addition to the enhancement of the quality of the prescription, our results indicate that pharmacist interventions provide a positive net cost benefit.
BACKGROUND: Potential inappropriate use of direct oral anticoagulants (DOACs) increases the risk of thromboembolic and haemorrhagic events. PURPOSE: To determine the net cost benefit of clinical pharmacy interventions on the prescription of DOACs. METHOD: We constructed a decision tree model using a public payer perspective. The appropriateness of the prescription was assessed using the Medication Appropriateness Index. The theoretical risks were collected from the literature and the individual potential risks were calculated using the Nesbit risk assignment conducted by two independent clinical pharmacists. Different costs were included based on diagnosis-related group coding and data in the literature. A univariate sensitivity analysis was performed. RESULTS: Thirty-six of 75 patients had an inappropriate prescription of DOACs. The saved difference between avoided costs (7954€) and annualised medication costs and pharmacist cost (4323€) was 3631€ for 75 patients. CONCLUSIONS: In addition to the enhancement of the quality of the prescription, our results indicate that pharmacist interventions provide a positive net cost benefit.
Authors: T W Nesbit; K M Shermock; M B Bobek; D L Capozzi; P A Flores; M C Leonard; J K Long; M A Militello; D A White; L D Barone; M P Goldman; D A Kvancz Journal: Am J Health Syst Pharm Date: 2001-05-01 Impact factor: 2.637
Authors: Anne-Sophie Larock; François Mullier; Anne-Laure Sennesael; Jonathan Douxfils; Bérangère Devalet; Christian Chatelain; Jean-Michel Dogné; Anne Spinewine Journal: Ann Pharmacother Date: 2014-06-30 Impact factor: 3.154
Authors: Meera Viswanathan; Leila C Kahwati; Carol E Golin; Susan J Blalock; Emmanuel Coker-Schwimmer; Rachael Posey; Kathleen N Lohr Journal: JAMA Intern Med Date: 2015-01 Impact factor: 21.873
Authors: Anders Gustavsson; Mikael Svensson; Frank Jacobi; Christer Allgulander; Jordi Alonso; Ettore Beghi; Richard Dodel; Mattias Ekman; Carlo Faravelli; Laura Fratiglioni; Brenda Gannon; David Hilton Jones; Poul Jennum; Albena Jordanova; Linus Jönsson; Korinna Karampampa; Martin Knapp; Gisela Kobelt; Tobias Kurth; Roselind Lieb; Mattias Linde; Christina Ljungcrantz; Andreas Maercker; Beatrice Melin; Massimo Moscarelli; Amir Musayev; Fiona Norwood; Martin Preisig; Maura Pugliatti; Juergen Rehm; Luis Salvador-Carulla; Brigitte Schlehofer; Roland Simon; Hans-Christoph Steinhausen; Lars Jacob Stovner; Jean-Michel Vallat; Peter Van den Bergh; Peter Van den Bergh; Jim van Os; Pieter Vos; Weili Xu; Hans-Ulrich Wittchen; Bengt Jönsson; Jes Olesen Journal: Eur Neuropsychopharmacol Date: 2011-09-15 Impact factor: 4.600
Authors: Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin Journal: N Engl J Med Date: 2011-08-27 Impact factor: 91.245